CRS and ICANS Management in CAR T/Bispecific Antibody Therapies

Nurses play an integral role in the identification and initial management of patients with suspected cytokine-release syndrome (CRS) and/or immune receptor cell associated neurotoxicity syndrome (ICANS). As these therapies continue to evolve, it is imperative that nursing policies are created/revised and shared with nursing staff to remain up to date on current clinical practice for these complications. With continued education and reinforcement of protocols, nurses can positively impact patient outcomes.

Target Audience

This program is designed to meet the educational needs of oncology nurses who treat patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify symptoms associated with a CRS or ICANS complication post CAR T-cells or bispecific T-cell engagers therapy.
  • Identify nursing interventions to support prompt response to potential CRS and/or ICANS in patients.
  • Identify tools useful in the grading of complications related to these therapies.

You may also be interested in

CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies

Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.
Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Refining Therapeutic Approaches in Relapsed/Refractory Multiple Myeloma: Expert Guidance on Bispecific Antibody Therapy Optimization
Expert faculty provide a comprehensive overview of bispecific antibodies in relapsed/refractory multiple myeloma, including clinical considerations, common toxicities, and prophylaxis and management strategies.
Additional information
Supporters: 

Supported by educational grants from AstraZeneca; Genentech, a member of the Roche Group; and Novartis. Supported by an independent medical education grant from ADC Therapeutics. Supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Course opens: 
06/15/2025
Course expires: 
03/01/2026
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2025 Nursing Program: Advancing Oncology Nursing™

Patricia A. Mangan, MSN, RN, APRN-BC, CRNP
Abramson Cancer Center at the University of Pennsylvania

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Amanda E. Visnick, RN, BSN, OCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 

Patricia A. Mangan, MSN, RN, APRN-BC, CRNP
Bristol Myers Squibb: Honoraria
Janssen Pharmaceutica Products, LP: Honoraria
Karyopharm Therapeutics: Honoraria

NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour. This activity offers 0.75 pharmacotherapeutic contact hour for nurses.

Available Credit

  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing